Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57

AP-1 CDKN1C FHL2 HDAC c-Jun coactivator p57 transcription

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 05 02 2021
accepted: 10 03 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

p57 is a member of the Cip/Kip family of cell cycle inhibitors which restrict the eukaryotic cell cycle by binding to and inhibiting cyclin/CDK complexes. They are considered as tumor suppressors and inactivating genomic mutations of p57 are associated with human overgrowth disorders. Increasing evidence suggests that p57 controls additional cellular processes beyond cell cycle control such as apoptosis, cell migration or transcription. Here we report that p57 can stimulate AP-1 promotor activity. While transactivation by c-Jun is strongly activated by p57, it did not enhance c-Fos induced transcription. This indicates that c-Jun is the target of p57 in the canonical AP-1 heterodimeric transcription factor. We could detect endogenous p57/c-Jun containing complexes in cells by co-immunoprecipitation. The strong stimulation of c-Jun activity is not the consequence of activating phosphorylation in the transactivation domain (TAD) of c-Jun, but rather due to negative interference with c-Jun repressors and positive interference with c-Jun activators. In contrast to full-length p57, the amino- and carboxy-terminal domains of p57 are insufficient for a significant activation of c-Jun induced transcription. When expressed in presence of full length p57, the p57

Identifiants

pubmed: 33928088
doi: 10.3389/fcell.2021.664609
pmc: PMC8076676
doi:

Types de publication

Journal Article

Langues

eng

Pagination

664609

Informations de copyright

Copyright © 2021 Kullmann, Pegka, Ploner and Hengst.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cell. 2007 Jan 26;128(2):269-80
pubmed: 17254966
Oncogene. 1995 Dec 21;11(12):2509-14
pubmed: 8545107
Genes Dev. 1999 Jun 15;13(12):1501-12
pubmed: 10385618
Cell Death Differ. 2009 Sep;16(9):1256-65
pubmed: 19590511
Trends Mol Med. 2014 Nov;20(11):614-22
pubmed: 25262539
Nat Genet. 1996 Oct;14(2):171-3
pubmed: 8841187
J Cell Biol. 1999 May 31;145(5):1049-61
pubmed: 10352021
EMBO J. 2003 Jul 15;22(14):3686-95
pubmed: 12853483
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2795-800
pubmed: 9501169
Biochim Biophys Acta. 2011 Aug;1816(1):50-6
pubmed: 21447370
J Cell Biol. 2002 Oct 14;159(1):113-22
pubmed: 12370240
Virology. 1973 Apr;52(2):456-67
pubmed: 4705382
Curr Top Microbiol Immunol. 1998;227:25-41
pubmed: 9479824
J Cell Sci. 2001 Jul;114(Pt 13):2363-73
pubmed: 11559745
Dev Biol. 1992 Jan;149(1):8-15
pubmed: 1728595
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Mol Cell Biol. 2000 Apr;20(8):2676-86
pubmed: 10733570
Oncogene. 2012 Sep 20;31(38):4207-20
pubmed: 22179826
Mol Cell Biol. 1999 Nov;19(11):7621-9
pubmed: 10523650
Microbiol Mol Biol Rev. 2016 Jul 27;80(3):793-835
pubmed: 27466283
Oncogene. 2001 Apr 30;20(19):2401-12
pubmed: 11402336
Sci Rep. 2020 Apr 28;10(1):7140
pubmed: 32346031
Am J Hum Genet. 1997 Aug;61(2):295-303
pubmed: 9311733
Nature. 1993 Sep 9;365(6442):179-81
pubmed: 8371760
Genes Dev. 1995 May 15;9(10):1149-63
pubmed: 7758941
PLoS One. 2014 May 19;9(5):e97764
pubmed: 24841113
J Biol Chem. 2000 Jun 23;275(25):18767-76
pubmed: 10764802
J Mol Biol. 2015 Jan 30;427(2):371-386
pubmed: 25463440
Mol Cell Biol. 1995 Apr;15(4):1907-14
pubmed: 7891684
Gene. 1989 Apr 15;77(1):51-9
pubmed: 2744487
Genes Dev. 1993 Nov;7(11):2135-48
pubmed: 8224842
Cancer Res. 2020 Sep 1;80(17):3451-3458
pubmed: 32341036
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):11-23
pubmed: 31034924
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14461-6
pubmed: 15452344
J Biol Chem. 2003 Nov 28;278(48):48092-8
pubmed: 12963725
EMBO J. 2003 Aug 1;22(15):3876-86
pubmed: 12881422
Front Cell Dev Biol. 2020 Oct 07;8:584590
pubmed: 33117811
Biochemistry. 2008 Jul 22;47(29):7598-609
pubmed: 18627125
Genes Dev. 2000 Jul 1;14(13):1553-77
pubmed: 10887150
Nature. 1997 May 8;387(6629):151-8
pubmed: 9144284
Cancer Res. 1995 Jan 15;55(2):348-53
pubmed: 7812967
Oncogene. 2011 Aug 11;30(32):3502-12
pubmed: 21423214
Cell Signal. 2010 Jun;22(6):894-9
pubmed: 20060892
Cell Cycle. 2002 Jan;1(1):39-41
pubmed: 12429907
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3977-82
pubmed: 12644711
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5192-7
pubmed: 19276117
Cells. 2020 Nov 13;9(11):
pubmed: 33202877
Genes Dev. 1997 Apr 15;11(8):973-83
pubmed: 9136926
Oncotarget. 2018 May 25;9(40):26259-26278
pubmed: 29899857
Nature. 2011 Jan 13;469(7329):231-5
pubmed: 21196933
Mol Cell Biol. 1987 Jun;7(6):2256-66
pubmed: 3037355
Genes Dev. 1995 Mar 15;9(6):650-62
pubmed: 7729684
Mol Endocrinol. 2008 Aug;22(8):1767-80
pubmed: 18535250
J Biol Chem. 2010 Mar 26;285(13):9813-9822
pubmed: 20106982
Nat Cell Biol. 2002 Aug;4(8):556-64
pubmed: 12134156
J Biochem. 2000 Jan;127(1):73-83
pubmed: 10731669
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7005-7014
pubmed: 30877256
J Pathol. 2016 Jul;239(3):250-61
pubmed: 27015986
Science. 1982 Jun 11;216(4551):1233-5
pubmed: 6177045

Auteurs

Michael Keith Kullmann (MK)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

Fragka Pegka (F)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

Christian Ploner (C)

Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Ludger Hengst (L)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

Classifications MeSH